[The influence of acemetacin and indometacin on gastrointestinal blood loss in normal volunteers and rheumatic patients (author's transl)].
In a clinical trial on 12 healthy volunteers total gastrointestinal blood loss was measured with 51Cr-labelled erythrocytes. This double-blind cross-over study showed a highly significant difference (p < 0.001) between indometacin and [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy[acetic acid (acemetacin, TV 1322, Rantudil¿) after oral application of 200 mg acemetacin, 200 mg indometacin per day and placebo for a week. Average total blood loss within seven days was 12.4 ml after indometacin, 4.5 ml after acemetacin and 5.0 ml after placebo. In a clinical trial on 16 rheumatic patients taking commercial non-steroidal antiinflammatory drugs over a long time total gastrointestinal blood loss was determined likewise. After a preceding wash-out period the blood loss due to acemetacin (240 mg daily) and indometacin (200 mg daily) for seven days was compared. There was a highly significant difference (p < 0.001) between both drugs. Total weekly blood loss was measured as 13.8 ml due to the treatment with indometacin and 6.5 ml due to acemetacin. During the wash-out period blood loss was detected as 6.0 ml weekly. There was no difference between the results of both trials. These clinical trials on 35 patients and volunteers do not give any indication that the new antiinflammatory drug acemetacin may cause mucosal lesions in the gastrointestinal tract evedenced by blood loss.